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ABSTRACT:
The HECT domain-containing ubiquitin E3 ligase NEDD4 is widely expressed 
in mammalian tissues and plays a crucial role in governing a wide spectrum of 
cellular  processes  including  cell  growth,  tissue  development  and  homeostasis. 
Recent reports have indicated that NEDD4 might facilitate tumorigenesis through 
targeted degradation of multiple tumor suppressor proteins including PTEN. However, 
the  molecular  mechanism  by  which  NEDD4  stability  is  regulated  has  not  been 
fully elucidated. Here we report that SCFβ-TRCP governs NEDD4 protein stability by 
targeting it for ubiquitination and subsequent degradation in a Casein Kinase-I (CKI) 
phosphorylation-dependent manner. Specifically, depletion of β-TRCP, or inactivation 
of CKI, stabilized NEDD4, leading to down-regulation of its ubiquitin target PTEN and 
subsequent activation of the mTOR/Akt oncogenic pathway. Furthermore, we found 
that CKIδ-mediated phosphorylation of Ser347 and Ser348 on NEDD4 promoted its 
interaction with SCFβ-TRCP for subsequent ubiquitination and degradation. As a result, 
compared to ectopic expression of wild-type NEDD4, introducing a non-degradable 
NEDD4 (S347A/S348A-NEDD4) promoted cancer cell growth and migration. Hence, 
our findings revealed the CKI/SCFβ-TRCP signaling axis as the upstream negative 
regulator of NEDD4, and further suggested that enhancing NEDD4 degradation, 
presumably with CKI or SCFβ-TRCP agonists, could be a promising strategy for treating 
human cancers. 
INTRODUCTION
Ubiquitination by the UPS (Ubiquitin Proteasome 
System)  is  a  post-translational  modification  that  has 
been demonstrated to regulate various cellular processes 
including cell proliferation, cell cycle progression and 
migration [1]. It is well known that the UPS consists of 
the  E1  ubiquitin-activating  enzyme,  the  E2  ubiquitin-
conjugating  enzyme  and  the  E3  ubiquitin  ligase  that 
interacts directly with the ubiquitin substrates [1]. As such, 
the specificity of targeted substrates is mainly determined 
by the E3 ligases [2]. E3 ubiquitin ligases are divided into 
multiple classes according to their functional domains, 
such as the Really Interesting New Gene (RING) type, 
Homologous to E6-AP Carboxyl-Terminus (HECT) type 
and Ring/Cullin Ligase (RCL)-type of E3 ligases. The E1 
enzyme activates the ubiquitin molecule and transfers it 
to the E2 enzyme. Subsequently, the charged E2 enzyme 
binds  a  specific  E3  ligase  and  transfers  the  ubiquitin 
directly  to  the  substrates  recruited  by  the  E3  ligase. Oncotarget 1027 www.impactjournals.com/oncotarget
However, for HECT-type E3 ligases including NEDD4, 
the ubiquitin molecule is transiently transferred from the 
charged E2 enzyme to a specific HECT domain-containing 
E3 ligase, which then relays the ubiquitin molecule to 
its substrates [1]. Ubiquitin-conjugated substrates have 
distinct fates depending on the linkage of their conjugated 
ubiquitin or poly-ubiquitin chain [3]. Specifically, Lys48-
linkage  or  Lys11-linkage  poly-ubiquitin  chains  are 
recognized by the 26S proteasome for degradation [4]. 
On the other hand, Lys63-linkage or linear (M1)-linkage 
chains were recently found to be functionally linked to 
enzymatic activation or DNA damage repair processes 
[5], whereas the functional significance of other atypical 
ubiquitin  linkages,  including  Lys6-linkage,  Lys27-
linkage, Lys29-linkage and Lys33-linkage, remain largely 
undefined [5].
The neural precursor cell-expressed developmentally 
downregulated gene 4 (NEDD4, also known as NEDD4-1) 
is the founding member of the family of HECT-type E3 
ligases [6]. The NEDD4 protein contains three functional 
domains: a C-terminal HECT domain for E2 binding and 
ubiquitin loading, an N-terminal C2 domain for membrane 
attachment, and a central WW domain largely mediating 
its interaction with substrates [7]. NEDD4 was initially 
identified to play a critical role in regulating neuronal 
function and plasticity in the brain [8]. It is noteworthy 
that NEDD4 also exerts its functions in protein trafficking 
by recycling proteins through the endocytic machinery [6]. 
Biochemically, multiple substrates of NEDD4 have been 
discovered including ENaC (epithelial sodium channel) 
[9],  AMPA  (Amino-3-hydroxy-5-methyl-isoxazole-4-
propionic acid) receptor [10, 11], Notch [12], IGF-1R 
(insulin-like growth factor-1 receptor) [13], VEGF-R2 
(vascular endothelial growth factor receptor-2) [14], Cbl-b 
[15], Deltex [12], EPS15 (epithelial growth factor receptor 
substrate 15) [16], Spy1A [17] and PTEN (phosphatase 
and tensin homologue) [18, 19]. The identification of these 
downstream targets have helped further understanding the 
physiological functions of NEDD4 in various cellular 
processes. For example, NEDD4 was found to govern 
sodium homeostasis largely through negatively controlling 
the expression levels of ENaC [9]. Moreover, it has been 
reported that NEDD4 antagonizes Notch signaling by 
promoting  the  degradation  of  Notch  and  Deltex  [12]. 
Notably,  multiple  laboratories  recently  identified  a 
possible oncogenic role for NEDD4 in part by promoting 
the ubiquitination of the PTEN tumor suppressor [18, 
19] to govern either its stability [19] or its subcellular 
localization [18]. Therefore, the NEDD4 E3 ligase might 
exert its physiological function largely through promoting 
the degradation of a broad range of downstream substrates. 
Given  its  critical  role  in  many  key  cellular 
processes, recent reports have suggested that NEDD4 
could be regulated by multiple means [20]. For instance, 
NEDD4 was found to be phosphorylated by Src [16], and 
could be cleaved by several caspases during apoptosis 
[21]. Furthermore, consistent with a possible oncogenic 
role for NEDD4, overexpression of NEDD4 was observed 
in human cancers such as prostate, bladder [22], colorectal 
[12]  and  non-small-cell  lung  carcinomas  (NSCLC) 
[23] and promoted growth of colon cancer cells [12]. 
Therefore,  targeted  reduction  of  NEDD4  expression 
might  be  a  promising  strategy  for  treatment  of  these 
human cancers. However, it remains largely unknown how 
NEDD4 stability is regulated physiologically, and how it 
becomes aberrantly upregulated in human cancers. In this 
study, we explored the molecular mechanisms underlying 
NEDD4 stability control and further examined whether 
alterations in regulation of NEDD4 expression contributes 
to tumorigenesis. To this end, our results identify that the 
ubiquitin E3 ligase SCFβ-TRCP governs NEDD4 protein 
stability  by  targeting  NEDD4  for  ubiquitination  and 
subsequent  destruction  in  a  CKI-dependent  manner. 
More importantly, dysregulated NEDD4 degradation led 
to reduction in PTEN expression and subsequent hyper-
activation of the oncogenic mTOR/Akt pathway, resulting 
in enhanced tumor cell proliferation and growth.
RESULTS
NEDD4 binds the SCFβ-TRCP ubiquitin E3 ligase 
complex
It  is  well  known  that  Cullin-Ring  complexes 
comprise the largest known group of E3 ubiquitin ligases 
[24].  Therefore,  we  first  explored  whether  a  specific 
Cullin-Ring E3 ligase might be involved in the regulation 
of NEDD4 destruction. By examining a panel of Cullin 
members,  we  observed  that  NEDD4  interacted  with 
Cullin-1, but not Cullin-2, Cullin-3, Cullin-4A or Cullin-5 
(Figure  1A).  Furthermore,  among  the  F-box  proteins 
examined, NEDD4 bound β-TRCP1 (Figure 1B), and to 
a much lesser extent, Fbl18 (Figure 1B). Consistent with 
this notion, NEDD4 interacted with β-TRCP1 at both 
endogenous (Figure 1C) and exogenous levels (Figure 
1D).  More  importantly,  a  mutant  form  of  β-TRCP1 
(R474A) deficient in binding substrates [25] exhibited 
significantly  reduced  ability  to  bind  NEDD4  (Figure 
1D and Supplementary Figure 1), supporting a specific 
and direct interaction between β-TRCP1 and NEDD4. 
Consistent with a role for substrate phosphorylation for 
β-TRCP  recognition  [26-29],  phosphatase  treatment 
led to a reduction in NEDD4 interaction with β-TRCP1 
(Figure  1E).  Notably,  we  also  observed  that  NEDD4 
interacted  with  the  SCF  E3  ligase  components  Rbx1 
(Figure 1F) and Skp1 (Figure 1G), further indicating the 
possible involvement of the complete SCFβ-TRCP complex 
in regulating NEDD4 abundance.   Oncotarget 1028 www.impactjournals.com/oncotarget
Depletion of β-TRCP led to increased NEDD4 
protein levels
To  validate  whether  NEDD4  is  a  potential 
physiological  substrate  for  β-TRCP,  we  examined 
NEDD4  protein  abundance  in  various  cell  lines  after 
depleting endogenous β-TRCP by multiple independent 
shRNAs (Supplementary Figures 2A-B). We observed 
that depletion of endogenous β-TRCP1, or both β-TRCP1 
and  β-TRCP2  (β-TRCP1+2)),  led  to  the  upregulation 
of NEDD4 protein levels in HeLa (Figure 2A), U2OS 
(Figure  2B)  and  293T  cells  (Supplementary  Figure 
2C). Furthermore, in keeping with previous reports that 
NEDD4 is a proto-oncogenic ubiquitin ligase for the tumor 
suppressor PTEN [18, 19], we observed that depletion of 
β-TRCP led to decreased levels of PTEN (Figures 2A 
and 2B) and subsequent elevated phosphorylation of Akt 
(Figure 2B). In further support of NEDD4 as a putative 
ubiquitin substrate for SCFβ-TRCP, depletion of endogenous 
Cullin1 also led to an accumulation of NEDD4 (Figure 2C 
and Supplementary Figure 2D). Moreover, consistent with 
a negative role of β-TRCP in regulating NEDD4 stability, 
depletion of endogenous β-TRCP1 dramatically increased 
NEDD4 protein half-life (Figures 2D and 2E) without 
significantly affecting NEDD4 mRNA levels (Figures 2F 
and 2G). Taken together, these results indicated that SCFβ-
TRCP  negatively regulates NEDD4 stability.   
Casein  Kinase  Iδ  (CKIδ)  promoted  the 
destruction of NEDD4 
As proper phosphorylation of substrates by specific 
kinase(s) is required for their recognition by the SCFβ-TRCP 
E3 ligase for subsequent ubiquitination and destruction 
[1], we explored the candidate kinases that are possibly 
involved in regulating the degradation of NEDD4 by SCFβ-
TRCP. To this end, we found that ectopic expression of CKIδ, 
but not CKIα, CK2, IKKα, ERK or GSK3β significantly 
reduced  NEDD4  protein  abundance  in  β-TRCP1-WT 
(Figure 3A), but not the β-TRCP1-R474A mutant (Figure 
3B) expressing cells. These results demonstrated that CKIδ 
might be the specific kinase that phosphorylates NEDD4 
to trigger its interaction with β-TRCP. Furthermore, we 
observed that only CKIδ, but not CKIα, CKIε or CKIγ 
interacted with NEDD4, further pinpointing CKIδ as the 
specific CKI isoform that might function as the upstream 
modifying enzyme to trigger ubiquitination of NEDD4 by 
SCFβ-TRCP (Figure 3C). To further validate the critical role 
of CKIδ in controlling NEDD4 stability, we inactivated 
CKIδ in HeLa cells by either shRNA-mediated depletion 
Figure 1: NEDD4 interacted with the SCFβ-TRCP ubiquitin E3 ligase complex. (A) Immunoblot (IB) analysis of whole cell 
lysates (WCL) and immunoprecipitates (IP) derived from 293T cells transfected with Myc-tagged Cullin constructs or empty vector (EV) 
as a negative control. (B) IB analysis of WCL and IP derived from 293T cells transfected with Flag-NEDD4 and the indicated GST-F-box 
protein constructs. (C) HeLa cell extracts were immunoprecipitated with antibody against NEDD4, or control IgG and analyzed by IB 
analysis. (D) IB analysis of WCL and IP derived from 293T cells transfected with HA-NEDD4 and Flag-tagged wild-type or R474A mutant 
β-TRCP1 constructs, or EV as a negative control. (E) IB analysis of WCL and IP derived from 293T cells transfected with HA-NEDD4 
and Flag-β-TRCP1 constructs. Where indicated, cell lysates were pre-treated with λ-phosphatase before the IP procedure. (F) IB analysis 
of WCL and IP derived from 293T cells transfected with HA-NEDD4 and Flag-Rbx1 constructs as indicated. (G) IB analysis of WCL and 
IP derived from 239T cells transfected with HA-NEDD4 and Myc-Skp1 constructs as indicated.Oncotarget 1029 www.impactjournals.com/oncotarget
of endogenous CKI (Figure 3D) or by a CKI specific 
pharmacological inhibitor, D4476 (Figure 3E), both of 
which led to elevated expression of NEDD4 (Figures 3D 
and 3E). These results cumulatively demonstrated that 
CKIδ might play a pivotal role in triggering the destruction 
of NEDD4 by SCFβ-TRCP.
CKIδ  phosphorylated  NEDD4  at  both  S347 
and  S348  to  promote  the  ubiquitination  and 
destruction of NEDD4 by SCFβ-TRCP
It  has  been  demonstrated  that  most  β-TRCP 
substrates contain a canonical DSGxxS degron sequence 
[30]. Unexpectedly, although human NEDD4 contains a 
canonical DSGxxS degron (Degron #2), it is not conserved 
among  various  species  including  rat,  mouse,  rabbit 
and  chicken  (Figure  4A).  However,  NEDD4  contains 
an evolutionally degenerate phospho-degron variant 
SSG (termed Degron #1, Figure 4A and Supplementary 
Figure 3A), which is also present in DEPTOR, a well 
characterized β-TRCP substrate [27, 31, 32]. Notably, 
Degron #1 exists in all four isoforms of human NEDD4 
(Supplementary  Figure  3A),  Given  that  isoform  4  of 
NEDD4 for has been previously described as a functional 
isoform [33], we used this isoform for all our studies. 
To  determine  which  degron,  when  phosphorylated,  is 
critical for governing NEDD4 stability, we mutated these 
Serine-347/Serine-348 (within Degron #1), Serine-408 
(within  Degron  #2)  to  alanines  to  generate  phospho-
deficient mutants. Interestingly, we found that the S347A/
S348A, but not the S408A mutation, led to a significantly 
decreased  interaction  between  NEDD4  and  β-TRCP1 
(Figure 4B and Supplementary Figure 3B), arguing for 
a critical role for the phosphorylation of S347/S348 in 
β-TRCP-mediated destruction of NEDD4. Consistently, 
compared  to  NEDD4-WT,  the  NEDD4-S347A/S348A 
mutant displayed resistance to β-TRCP1/CKIδ-mediated 
Figure 2: Depletion of β-TRCP increased NEDD4 protein levels. (A) Immunoblot (IB) analysis of whole cell lysates (WCL) 
derived from HeLa cells infected with shRNA constructs specific for GFP, β-TRCP1 (four independent lentiviral β-TRCP1-targeting 
shRNA constructs named -A, -B, -C, -D), β-TRCP2 or β-TRCP1+2, followed by selection with 1 µg/ml puromycin for three days to 
eliminate the non-infected cells. (B) IB analysis of WCL derived from U2OS cells infected with shRNA constructs specific for GFP, 
β-TRCP1 or β-TRCP1+2, followed by selection with 1 µg/ml puromycin for three days to eliminate non-infected cells. (C) IB analysis of 
WCL from 293T cells transfected with shRNA specific for GFP or several shRNA constructs against Cullin 1 (four independent lentiviral 
Cullin 1-targeting shRNA constructs named -A, -B, -C, -D) followed by selection with 1 µg/ml puromycin for three days to eliminate 
non-infected cells. (D) HeLa cells were infected with the shRNA constructs for GFP or β-TRCP1 followed by selection with 1 µg/ml 
puromycin for three days to eliminate non-infected cells. The generated stable cell lines were then split into 60-mm dishes. 20 hours later, 
cells were treated with 20μg/ml cycloheximide (CHX). At the indicated time points, WCLs were prepared and immunoblots were probed 
with the indicated antibodies. (E) Quantification of the band intensities in (D). NEDD4 band intensity was normalized to Vinculin, and then 
normalized to the t = 0 controls. The error bars represent mean ± SD (n = 3).  (F-G) Relative mRNA levels of β-TRCP1 (F) or NEDD4 (G) 
in HeLa cells infected with shRNA constructs specific for GFP, β-TRCP1 (-A and -B) or β-TRCP1+2 followed by selection with 1 µg/ml 
puromycin for three days to eliminate the non-infected cells. NEDD4 and β-TRCP1 mRNA levels were normalized to GAPDH, and then 
normalized to the control cells (shGFP). The error bars represent mean ± SD (n = 3).Oncotarget 1030 www.impactjournals.com/oncotarget
degradation  (Figure  4C).  Moreover,  this  degradation 
process  was  efficiently  blocked  by  the  proteasome 
inhibitor MG132, indicating the involvement of the 26S 
proteasome  and  ubiquitin  system  in  β-TRCP1/CKIδ-
mediated  degradation  of  NEDD4  (Figure  4C).  More 
importantly,  compared  to  NEDD4-WT,  the  NEDD4-
S347A/S348A  mutant  was  deficient  in  undergoing 
poly-ubiquitination as detected by in vivo ubiquitination 
assays (Figure 4D). Taken together, our results indicate 
that CKIδ can phosphorylate NEDD4 at the S347/S348 
sites within the putative degenerate Degron #1, to trigger 
the interaction of NEDD4 with β-TRCP for subsequent 
ubiquitination and destruction events. 
Loss of β-TRCP-mediated degradation of NEDD4 
promoted cancer cell growth and migration
It has been reported that NEDD4 plays an important 
role in facilitating the progression of breast and prostate 
cancers [22, 34]. Therefore, we next explored whether 
β-TRCP1-mediated  NEDD4  destruction  is  involved 
in cancer cell growth and migration. To this end, we 
retro-virally  expressed  a  non-degradable  mutant  form 
of  NEDD4  (NEDD4-S347A/S348A,  referred  to  as 
NEDD4-AA)  or  wild-type  NEDD4  (NEDD4-WT) 
in  the  breast  cancer  cell  line  MDA-MB-231  and  the 
prostate  cancer  cell  line  DU145.  Notably,  we  found 
that  NEDD4-AA  expressing  MDA-MB-231  cells  and 
DU145  cells  displayed  an  enhanced  migration  ability 
compared to NEDD4-WT or EV infected cells (Figures 
5A and 5B). Furthermore, NEDD4-AA expressing cells 
formed more colonies in soft agar (Figures 5C, 5D and 
Supplementary Figures 4A-B) and displayed elevated S 
phase entry (Figures 5E, 5F and Supplementary Figures 
4C-D)  than  cells  infected  with  NEDD4-WT  or  EV 
controls. Consistent with the observation that depletion 
of β-TRCP led to PTEN down-regulation and subsequent 
elevation of p-Akt largely via stabilizing NEDD4 (Figure 
2B), we found that in both MDA-MB-231 and DU145 
cells, ectopic expression of the non-degradable NEDD4 
mutant  (NEDD4-AA)  reduced  PTEN  expression  that 
subsequently led to Akt activation (Supplementary Figure 
4E-F). These results provided a possible mechanism for 
the observed enhanced tumorigenicity of NEDD4-AA-
expressing MDA-MB-231 and DU145 cells (Figures 5A-
G, and Supplementary Figures 4A-D). Taken together, 
these results suggest that by evading β-TRCP-mediated 
Figure 3: Casein Kinase Iδ (CKIδ) negatively controlled NEDD4 stability. (A) Immunoblot (IB) analysis of whole cell lysates 
(WCL) derived from 293T cells transfected with HA-NEDD4, Flag-β-TRCP1 and the indicated kinases. (B) IB analysis of WCL derived 
from 239T cells transfected with HA-NEDD4 and/or Myc-CKIδ together with Flag-WT–β-TRCP1 or Flag-R474A–β-TRCP1. (C) IB 
analysis of WCL and immunoprecipitates (IP) derived from HeLa cells transfected with HA-NEDD4 and Myc-tagged versions of the 
indicated CKI isoforms. (D) IB analysis of HeLa cells that were infected with shRNA specific for GFP or the indicated CKI isoforms, 
followed by selection with 1 µg/ml puromycin for three days to eliminate non-infected cells. (E) IB analysis of 293T cells treated with the 
CKI inhibitor D4476 at the indicated concentrations for 12 hours. Oncotarget 1031 www.impactjournals.com/oncotarget
degradation, cells expressing the non-degradable version 
of NEDD4 (NEDD4-AA) have increased cell growth and 
cell migration, presumably through the activated mTOR/
Akt pathway by suppressing the PTEN tumor suppressor. 
Furthermore,  as  illustrated  in  Figure  5G,  ectopic 
expression of NEDD4-AA in MDA-MB-231 cells also 
significantly enhanced cell proliferation. Altogether, these 
data suggest that β-TRCP-mediated destruction of the 
NEDD4 oncoprotein could inhibit cell proliferation and 
migration and bypassing this negative regulation could 
possibly facilitate tumorigenesis (Figure 6). 
DISCUSSION
In  the  present  study,  for  the  first  time,  we 
provide evidence for a mechanism by which SCFβ-TRCP 
controls NEDD4 protein stability in a CKIδ-dependent 
manner.  In  support  of  this  concept,  we  observed  that 
depletion  of  β-TRCP  (Figures  2A-B)  or  inactivation 
of CKIδ (Figures 3A and 3D-E) led to accumulation of 
NEDD4  and  subsequent  down-regulation  of  its  well 
characterized substrate, PTEN, leading to the activation 
of the downstream oncogenic mTOR/Akt pathway. More 
importantly, our results showed that CKIδ phosphorylates 
NEDD4 at both the Ser347 and Ser348 sites to trigger 
NEDD4  ubiquitination  by  SCFβ-TRCP and subsequent 
destruction by the 26S proteasome (Figures 4B and 4C). 
Consistent with a critical role of NEDD4 phosphorylation 
in triggering its degradation, introducing a non-degradable 
NEDD4 mutant (S347A/S348A) promoted cancer cell 
growth and migration in both PTEN positive prostate 
and breast cancer cells (Figure 5). Our findings therefore 
demonstrate that NEDD4 may be a potential target in the 
treatment of human cancers. 
Previous studies have shown that NEDD4 could 
be regulated by various means [35, 36]. For example, 
Forkhead box protein M1B (FoxM1B) promoted NEDD4 
expression, leading to cellular transformation and full 
malignant phenotype in immortalized human astrocytes 
[35]. Similarly, NDRG1 (N-myc downstream regulated 
gene-1)  could  also  regulate  NEDD4  expression  in 
pancreatic cancer cells [36]. Our study here demonstrated 
that besides transcriptional regulation, NEDD4 turnover 
is also controlled by β-TRCP in a CKI phosphorylation-
dependent manner. Importantly, recent studies have begun 
to reveal that NEDD4 might function as an oncoprotein 
that  is  frequently  overexpressed  in  human  tumors 
Figure 4: CKIδ phosphorylated NEDD4 at S347/S348 sites to facilitate its ubiquitination and subsequent destruction 
by SCFβ-TRCP. (A) Alignment of the candidate phospho-degron sequences in NEDD4 from different species. (B) Immunoblot (IB) analysis 
of whole cell lysates (WCL) and immunoprecipitates (IP) derived from HeLa cells transfected with Flag–β-TRCP1 together with HA-
WT-NEDD4, HA-S408A-NEDD4 or HA-S347A/S348A-NEDD4. (C) IB analysis of HeLa cells transfected with Flag-β-TRCP1 and HA-
tagged wild-type, S408A, or S347A/S348A mutant forms of NEDD4. Where indicated, cells were treated with Myc-CKIδ, or treated with 
the proteasome inhibitor MG132 before harvesting. (D) IB analysis of WCL and IP derived from HeLa cells transfected with Flag-β-
TRCP1, His-Ubiquitin, and HA-tagged wild-type or S347A/S348A mutant NEDD4 constructs, or EV (as a negative control) as indicated. Oncotarget 1032 www.impactjournals.com/oncotarget
[12, 22, 23]. Mechanistically, NEDD4 might exert its 
oncogenic role in part through degradation of its target 
proteins such as LATS1 and PTEN [18, 37]. Salah et 
al. reported that NEDD4 directly interacts with LATS1, 
leading to ubiquitination and decreased levels of LATS1, 
thus inhibiting the activity of the Hippo pathway [37]. 
Similarly, several studies have shown that NEDD4 is a 
PTEN negative regulator in human malignancies [23, 38-
41]. In support of this notion, NEDD4 overexpression was 
observed to positively correlate with the loss of PTEN in 
human cancer [38, 41, 42]. In line with this finding, we 
found that depletion of β-TRCP caused increased NEDD4 
Figure 5: Loss of SCFβ-TRCP-mediated degradation of NEDD4 promoted cancer cell proliferation and migration.  (A-
B) Scratch assays were performed with MDA-MB-231 cells that were infected with EV, HA-wild-type (WT)-NEDD4 or HA-S347A/
S348A (AA)-NEDD4 encoding retroviral vectors followed by 3 days of puromycin (1 µg/ml) selection to eliminate non-infected cells. The 
generated various MDA-MB-231 cell lines were seeded on a 6-well plate and scratched on the surface with a pipette tip. Relative values 
were set at 1 for the gap width at the time of the scratch. Representative photographs at time points 0, 9 and 24 hours after the scratch 
(A). Measurements were done in duplicate in 3 separate experiments, and data were depicted as average gap width (B). The error bars 
represented mean ± SD (n = 3), * p<0.05 (Student’s t-test), compared with cells expressing WT-NEDD4. (C-D) Colony formation assays 
were performed with the MDA-MB-231 cell lines generated in (A). After 4 days, the colonies were stained with crystal violet and counted 
(C). The number of surviving colonies were calculated as the average of triplicates (D). The error bars represented mean ± SD (n = 3), * 
p<0.05 (Student’s t-test), compared with cells expressing WT-NEDD4. (E-F) BrdU labeling analysis was performed with MDA-MB-231 
cell lines generated in (A). Cells were incubated with BrdU and uridine for 48 hours and representative photographs were taken (E). 
Percentage of BrdU positive cells was illustrated in (F). The error bars represented mean ± SD (n = 3), * p<0.05 (Student’s t-test), compared 
with cells expressing WT-NEDD4. (G) MDA-MB-231 cells stably expressing control EV, HA-WT-NEDD4 or HA-S347A/S348A-NEDD4 
were seeded and analyzed for cell proliferation capacities. The data shown are derived from three independent experiments, and the error 
bars represented mean ± SD. (* p<0.05, compared with cells expressing WT-NEDD4; Student’s t-test).Oncotarget 1033 www.impactjournals.com/oncotarget
abundance and a subsequent decrease in PTEN expression, 
which in turn led to hyper-activation of its downstream 
signaling component, Akt, to promote cell survival and 
proliferation.
NEDD4  has  been  previously  found  to  be 
overexpressed in colorectal cancers and promoted growth 
of  colon  cancer  cells  [12].  Similarly,  suppression  of 
NEDD4 expression significantly inhibited proliferation of 
NSCLC cells in vitro and tumor growth in vivo, whereas 
NEDD4 overexpression augmented the tumorigenicity 
of  lung  cancer  cells  with  an  intact  PTEN  gene  [23]. 
Consistent with these reports, we observed that ectopic 
expression of non-degradable NEDD4-AA significantly 
promoted cell growth compared to cells expressing WT-
NEDD4 (Figures 5C-G). Notably, we found that cells 
expressing NEDD4-AA had increased cellular migration 
ability (Figures 5A-B). As NEDD4 negatively regulates 
PTEN  stability,  NEDD4  could  possibly  promote  cell 
growth and migration partly through activation of the 
mTOR/Akt  pathway  in  prostate  and  breast  cancers. 
However,  further  in-depth  investigation  is  required  to 
explore  whether  NEDD4  promotes  cell  invasion  and 
metastasis in other human cancers, and its dependence on 
activation of the mTOR/Akt oncogenic signaling pathway. 
In  summary,  our  results  indicate  that  β-TRCP 
governs NEDD4 stability in a CKIδ phosphorylation-
dependent manner. Therefore, drugs that could induce 
NEDD4  degradation  through  upregulated  expression 
or activating -TRCP1 or CKIδ, could be useful to treat 
human cancers with high expression of NEDD4. Hence, 
our findings suggest that targeting NEDD4 destruction 
could be a promising approach to achieve better treatment 
outcomes in human cancers.  
MATERIALS AND METHODS
Cell culture
DU145 cells were cultured in RPMI 1640 medium 
(Life Technologies, CA) supplemented with 10% FBS, 
penicillin  and  streptomycin.  HeLa,  293T,  MCF-7  and 
MDA-MB-231 cells were cultured in DMEM medium 
(Life Technologies, CA) supplemented with 10% FBS, 
penicillin and streptomycin. The cells were maintained in 
a 5% CO2-humidified atmosphere at 37°C, as previously 
described [26, 28, 29].
Plasmids
PCI-HA-NEDD4  was  obtained  from  Addgene 
(27002) [33]. Various NEDD4 mutants were generated 
using the QuikChange XL Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s instructions. 
Lentiviral short hairpin RNAs (shRNA lentiviral vectors) 
against GFP, β-TRCP1, β-TRCP1+2 and various CKI 
isoforms  were  described  previously  [43,  44].  Flag-β-
TRCP1  and  Flag-β-TRCP1-R474A  constructs  were 
described  previously  [30,  45].  Myc-Cullin  1,  Myc-
Cullin 2, Myc-Cullin 3, Myc-Cullin 4 and Myc-Cullin 5 
constructs were obtained from James DeCaprio (Dana-
Farber Cancer Institute, Boston, MA). Lentiviral shRNA 
constructs against GFP and various CKI isoforms were 
gifts from William Hahn (Dana-Farber Cancer Institute, 
Boston, MA). shRNA lentiviral vectors against Cullin 1 
were gifts from J. Wade Harper (Harvard Medical School, 
Boston, MA).
Antibodies and reagents
Anti-NEDD4  (4013),  anti-PTEN  (9188),  anti-
Akt1 (2938), anti-pAkt (S473) (9018), anti-pAkt (T308) 
(13038),  anti-p-FOXO3a  (T32)  (9464),  anti-FOXO3a 
(2497) and anti-Cdc25A (3652) antibodies were purchased 
from Cell Signaling Technology. Anti-c-Myc (9E10) and 
polyclonal anti-HA antibodies (SC-805) were purchased 
from Santa Cruz Biotechnology. Anti-Vinculin antibody 
(V-4505),  polyclonal  anti-Flag  antibody  (F-2425), 
monoclonal anti-Flag antibody (F-3165), anti-HA agarose 
beads  (A-2095),  peroxidase-conjugated  anti-mouse 
secondary antibody (A-4416) and peroxidase-conjugated 
anti-rabbit secondary antibody (A-4914) were purchased 
from Sigma. Anti-GFP antibody (632380) was obtained 
from Invitrogen. Anti-Cullin 1 (4995) and anti–β-TRCP1 
(4394) antibodies were purchased from Cell Signaling 
Technology.  Monoclonal  anti-HA  antibody  (MMS-
Figure 6: A proposed model for how bypassing SCFβ-
TRCP-mediated ubiquitination and degradation of the 
NEDD4 oncoprotein might promote tumorigenesis in 
part  through  elevating  the Akt  oncogenic  signaling 
pathway  by  downregulating  the  PTEN  tumor 
suppressor.Oncotarget 1034 www.impactjournals.com/oncotarget
101P)  was  purchased  from  Covance.  Oligofectamine, 
Lipofectamine and Plus reagents were purchased from 
Life Technologies. 
Immunoblot and immunoprecipitation
Cells were lysed in EBC lysis buffer (50 mM Tris 
pH 8.0, 120 mM NaCl, 0.5% NP-40) supplemented with 
protease inhibitors (Roche) and phosphatase inhibitors 
(EMD  Millipore).  The  protein  concentrations  were 
measured using the Bio-Rad protein assay reagent (Bio-
Rad Laboratories, CA). The lysates were then resolved 
by SDS-PAGE (sodium dodecyl sulfate polyacrylamide 
gel electrophoresis) and immunoblotted with indicated 
antibodies  as  described  previously  [26,  28,  29].  For 
immunoprecipitation  assays,  800  µg  lysates  were 
incubated with the appropriate antibody (1-2 µg) overnight 
at 4 °C followed by addition of Protein A sepharose beads 
for one hour. Immunocomplexes were resolved by SDS-
PAGE and immunoblotted with indicated antibodies after 
washed with NETN buffer (20 mM Tris, pH 8.0, 100 mM 
NaCl, 1 mM EDTA and 0.5% NP-40).  
Protein degradation analysis
Cells were transfected with plasmids encoding PCI-
HA-NEDD4, Flag-β-TRCP1 and GFP as a transfection 
control, in the presence or absence of Myc-CKIδ. After 
40 hours, cells were lysed and immunoblot analysis was 
performed. For half-life studies, 20 µg/ml cycloheximide 
(CHX, Sigma C7698) was added to the medium 40 hours 
post-transfection, cells were then lysed at the indicated 
time points and immunoblot analysis was conducted to 
detect protein abundances. 
In vivo ubiquitination assays
Cells  were  transfected  with  His-Ubiquitin  along 
with HA-NEDD4 (wild-type or S347A/S348A) and Flag-
β-TRCP1. 36 hours post-transfection, cell lysates were 
incubated with Ni-NTA matrices (Qiagen) at 4 °C for 12 
hours in the presence of 8 M Urea (pH 7.5) as described 
previously  [46].  Then,  immobilized  proteins  were 
immunoblotted with the anti-HA antibody after washed 
five times with 8 M urea at pH 6.3.
Cell transfection
Cells were transfected using Lipofectamine (Life 
Technologies) in OptiMEM medium (Life Technologies) 
according to the manufacturer’s instructions. 48 hours 
post-transfection, transfected cells were further subjected 
to Real-time RT-PCR or immunoblot analysis to detect the 
efficacy of transfection. 
Scratch assays
Cancer  cells  were  cultured  in  6-well  plate  until 
the cells grew to confluence. The scratch wound was 
scraped in a straight line using a pipette tip. Photographic 
images were taken at 0 hour and 18 hours. Gap width 
measurements were conducted with Photoshop CS4 using 
the analytical ruler tool. 
Colony formation assays
Cancer cells were seeded into gelatinized plates. 
After  7  days,  the  colonies  were  stained  with  crystal 
violet and counted. The numbers of surviving colonies 
were calculated as the average of triplicates as described 
previously [26].
Bromodeoxyuridine (BrdU) labeling assays
Cells were incubated with BrdU and uridine for 48 
hours. Then the BrdU labeling assay was performed as 
described previously [47].
Real-time RT-PCR
RNA was extracted using the Qiagen RNeasy mini 
kit, and the reverse transcription reaction was performed 
using the ABI Taqman Reverse Transcription Reagent 
(N808-0234).  The  real-time  RT-PCR  reaction  was 
performed with the ABI-7500 Fast Real-time PCR system 
as described previously [48]. 
Statistical Analysis
All quantitative data were presented as the mean ± 
SD as indicated of at least three independent experiments 
by Student’s t test for between group differences. p < 0.05 
was considered as statistically significant.
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